Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 171-185

  Östenson, Claes Göran ^a   Matthaei, Stephan ^b   Reaney, Matthew ^c   Krarup, Thure ^d   Guerci, Bruno ^e   Kiljanski, Jacek ^f   Salaun Martin, Carole ^g   Sapin, Hélène ^g   Bruhn, David ^c   Mathieu, Chantal ^h   Theodorakis, Michael ⁱ  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Diabetes Zentrum Quakenbruck   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d BISPEBJERG HOSPITAL   (Denmark)

^e CHU NANCY BRABOIS   (France)

^f Eli Lilly Polska Sp z oo   (Poland)

^g Eli Lilly   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Exenatide; Injectable therapy; Insulin; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; INSULIN; SULFONYLUREA;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; EUROPE; FEMALE; HEARTBURN; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SIDE EFFECT; TASTE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 84876908661     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/DMSO.S41827     Document Type: Article

References (46)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
3. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333-2348.
4. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559-569.
5. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-267.
6. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11:1153-1162.
7. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
8. Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-2055.
9. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. NICE short clinical guideline 87. London: NICE; 2009 Available from: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf. Accessed January 23, 2013.
10. Bergenstal RM, Garrison LP Jr, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27(3):531-540.
11. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777-786.
12. Ryder RE, Thong KY, Cull ML, Mills AP, Walton C, Winocour PH. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int. 2010;27(8):352-357b.
13. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.
14. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
15. Yurgin N, Secnik K, Lage MJ. Obesity and the use of insulin: a study of patients with type 2 diabetes in the UK. J Diabetes Complications. 2008;22(4):235-240.
16. Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146(4):2069-2076.
17. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77-88.
18. Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34 Suppl 2:S258-S263.
19. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278(1):471-478.
20. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270-2276.
21. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14(9):810-820.
22. European Medicines Agency. Byetta: exenatide; assessment history [web page on the Internet]. London: European Medicines Agency; nd. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human_med_000682.jsp&jsenabled=true. Accessed December 10, 2012.
23. Lilly. Byetta® approved for use with basal insulin in Europe [press release]. San Diego, CA: Amylin Pharmaceuticals; 2012 [March 23]. Available from: https://investor.lilly.com/releasedetail2.cfm?ReleaseID=659089. Accessed December 10, 2012.
24. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec No:1284-1292.
25. Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20(1): 54-60.
26. Amylin Pharmaceuticals. CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated April 12, 2010]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00635492. NLM identifier: NCT00635492. Accessed February 23, 2013.
27. Matthaei S, Reaney M, Mathieu C, et al. Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Ther. 2012;3(1):6.
28. Bergenstal RM, Garrison LP Jr, Miller LA, et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27(12):2335-2342.
29. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25(3):691-700.
30. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17(1):1-13.
31. Simpson A, Smith H, Nicolay C, et al. Approaches to initiation of insulin therapy in patients with type 2 diabetes and resulting outcomes at 12 months in four European countries: data from the INSTIGATE study. Poster presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), October 30-November 2, 2008, Barcelona, Spain.
32. Benroubi M, Schmitt H, Cleall SP, et al; the TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: results from the TREAT study. Poster presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, September 12-16, 2011, Lisbon, Portugal.
33. Blak BT, Smith HT, Hards M, Maguire A, Gimeno V. A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabet Med. 2012;29(8):e191-e198.
34. Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract. 2010; 64(12):1609-1618.
35. Hall GC, McMahon AD, Dain MP, Home PD. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract. 2011;94(3):442-448.
36. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-2635.
37. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091.
38. Buysschaert M, Preumont V, Oriot PR, et al; UCL Study Group for Exenatide. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5): 381-388.
39. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762-768.
40. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
41. Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J. 2009;85(1003):257-267.
42. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166(2):159-170.
43. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1-248.
44. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of,7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1): 77-82.
45. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 Suppl 1:S11-S63.
46. Ryder RE, Thong K; ABCD nationwide exenatide and liraglutide audit contributors. ABCD nationwide exenatide and liraglutide audits. Presented at Diabetes UK Annual Professional Conference, March 30-April 1, 2011, London, UK.